GoodRx Holdings, Inc. (GDRX) Stock Forecast
Data as of Jun 17, 2026Healthcare · Current price $2.72 (-0.55%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 26, 2026 | Michael Cherny | Leerink Partners | $3.00 | +10.3% |
| Jan 22, 2026 | Glen Santangelo | Jefferies | $2.75 | +1.1% |
| Aug 11, 2025 | George Hill | Deutsche Bank | $6.00 | +120.6% |
| Jun 10, 2024 | Craig Hettenbach | Morgan Stanley | $9.50 | +249.3% |
| May 23, 2024 | Mark Mahaney | RBC Capital | $10.00 | +267.6% |
| May 16, 2024 | Stephanie Davis | Barclays | $9.00 | +230.9% |
| May 16, 2024 | Aaron Kessler | Raymond James | $10.00 | +267.6% |
| Apr 10, 2024 | Scott Schoenhaus | BOCOM International Holdings Company | $9.00 | +230.9% |
| Mar 25, 2024 | Stan Berenshteyn | Wells Fargo | $10.00 | +267.6% |
| Nov 13, 2023 | Eric Sheridan | Goldman Sachs | $3.00 | +10.3% |
| Aug 9, 2022 | Steve Valiquette | Barclays | $13.00 | +377.9% |
| Jun 7, 2022 | Vikram Kesavabhotla | Robert W. Baird | $7.00 | +157.4% |
| May 12, 2022 | Stan Berenshteyn | Wells Fargo | $9.00 | +230.9% |
| Mar 1, 2022 | Doug Anmuth | J.P. Morgan | $20.00 | +635.3% |
| Mar 1, 2022 | Charles Rhyee | Cowen & Co. | $22.00 | +708.8% |
| Mar 1, 2022 | Eric Sheridan | Goldman Sachs | $30.00 | +1002.9% |
| Mar 1, 2022 | George Hill | Deutsche Bank | $20.00 | +635.3% |
| Mar 1, 2022 | Justin Post | Bank of America Securities | $28.00 | +929.4% |
| Dec 21, 2021 | Scott Schoenhaus | Stephens | $45.00 | +1554.4% |
| May 14, 2021 | Nicholas Jones CFA | Citigroup | $53.00 | +1848.5% |
Top Analysts Covering GDRX
GDRX vs Sector & Market
| Metric | GDRX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.50 | 2.24 | 2.40 |
| Analyst Count | 10 | 8 | 19 |
| Target Upside | +25.1% | +11475.0% | +17.1% |
| P/E Ratio | 47.09 | 3.87 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $755M | $765M | $767M | 11 |
| 2027-03-31 | $190M | $195M | $200M | 5 |
| 2027-06-30 | $197M | $201M | $206M | 5 |
| 2027-09-30 | $199M | $204M | $209M | 5 |
| 2027-12-31 | $204M | $209M | $214M | 5 |
| 2028-03-31 | $206M | $211M | $216M | 4 |
| 2028-06-30 | $213M | $218M | $223M | 4 |
| 2028-09-30 | $218M | $223M | $229M | 4 |
| 2028-12-31 | $226M | $232M | $238M | 4 |
| 2029-12-31 | $902M | $926M | $946M | 5 |
| 2030-12-31 | $892M | $915M | $935M | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $0.27 | $0.32 | $0.38 | 9 |
| 2027-03-31 | $0.08 | $0.08 | $0.09 | 3 |
| 2027-06-30 | $0.09 | $0.10 | $0.10 | 5 |
| 2027-09-30 | $0.10 | $0.10 | $0.11 | 3 |
| 2027-12-31 | $0.11 | $0.11 | $0.11 | 6 |
| 2028-03-31 | $0.11 | $0.12 | $0.12 | 4 |
| 2028-06-30 | $0.14 | $0.14 | $0.15 | 6 |
| 2028-09-30 | $0.16 | $0.16 | $0.17 | 4 |
| 2028-12-31 | $0.17 | $0.18 | $0.18 | 7 |
| 2029-12-31 | $0.86 | $0.89 | $0.91 | 4 |
| 2030-12-31 | $0.00 | $0.00 | $0.00 | 2 |
Frequently Asked Questions
What is the analyst consensus for GDRX?
The consensus among 10 analysts covering GoodRx Holdings, Inc. (GDRX) is Buy with an average price target of $3.25.
What is the highest price target for GDRX?
The highest price target for GDRX is $53.00, set by Nicholas Jones CFA at Citigroup on 2021-05-14.
What is the lowest price target for GDRX?
The lowest price target for GDRX is $2.75, set by Glen Santangelo at Jefferies on 2026-01-22.
How many analysts cover GDRX?
10 analysts have issued ratings for GoodRx Holdings, Inc. in the past 12 months.
Is GDRX a buy or sell right now?
Based on 10 analyst ratings, GDRX has a consensus rating of Buy (2.50/5) with a +25.1% upside to the consensus target of $3.25.
What are the earnings estimates for GDRX?
Analysts estimate GDRX will report EPS of $0.32 for the period ending 2026-12-31, with revenue estimated at $765M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.